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As regards the interesting discovery of a
novel BRCA1 mutation in a family of
Palestinian Arabian origin (Kadouri et al.,
2007), we would like to state that all
gene mutations bring about necessarily
local biological activity modification, oth-
erwise, genemutations would bemeaning-
less innocent bystanders (Stagnaro-Neri
and Stagnaro, 1995; Kadouri et al., 2007;
Stagnaro, 2008).
In the present article we suggest an
original clinical tool for the diagno-
sis of Inherited Real Risk (IRR) of
breast cancer which can support the cur-
rent sophisticated ways for breast cancer
risk assessment such as, e.g., the tradi-
tional breast physical examination, and
the denaturing high performance liquid
chromatography (DHPLC) to screen for
mutations of BRCA1- BRCA-2 (Kadouri
et al., 2007), which have been linked
to hereditary breast and ovarian cancer,
and inheriting this mutation increases the
risk of developing breast/ovarian cancer.
Furthermore, this last evaluation is expen-
sive for National Health Service (NHS),
and not applicable for all women andmen.
Quantum Biophysical Semeiotics
(QBS) theory provides a clinical, reli-
able method both for bed-side diagnosis
and breast cancer primary and pre-




QBS is a new discipline in medical field
and an extension of the classical medi-
cal semeiotics with the support of quan-
tum and complexity theories (Caramel
and Stagnaro, 2011). It is a scientific trans-
disciplinary approach that is based on the
“Congenital Acidosic Enzyme-Metabolic
Histangiopathy” (CAEMH) (Stagnaro and
Caramel, 2010), a unique mitochondrial
cytopathy that is present at birth and sub-
ject to medical therapy. The presence of
intense CAEMH in a well-defined area
(e.g., myocardium) is due to gene muta-
tions in both n-DNA and mit-DNA.
This is the basis for one or more QBS
constitutions (Stagnaro and Stagnaro-
Neri, 2004b), in our case, Oncological
Terrain (Stagnaro, 2004), which could
bring about their respective IRR, i.e., IRR
of cancer (Stagnaro, 2009; Stagnaro and
Caramel, 2012, 2013a,b). TheQBSmethod
allows the clinical and pre-clinical diagno-
sis of the most severe diseases such as
the IRR of breast cancer (Stagnaro, 2004,
2005a,b,c,d), which is achieved in the
easier way through the auscultatory per-
cussion of the stomach (Stagnaro, 1985,
2005e). The patho-physiology of QBS
reflexes is based upon local microvascu-
lar conditions. In case of genetic alteration
of both DNAs, intense CAEMH, and IRR
of breast cancer there is a microcircula-
tory remodeling, worsened by well-known
environmental risk factors, due to vaso-
motility and vasomotion impairment
(e.g., functional imperfection) and struc-
tural obstructions, i.e., pathological
Endoarteriolar Blocking Devices (EBDs)
and Arteriovenous Anastomosis (AVA)
(Stagnaro and Stagnaro-Neri, 2004a;
Stagnaro, 2009; Stagnaro and Caramel,
2010).
With the aid of QBS method, physi-
cians can bedside recognize, in an easy,
quick, and reliable manner, the pos-
sible presence of maternally-inherited
Oncological Terrain, and Oncological
terrain-dependent, IRR, based on the
presence of typical microcirculatory
remodeling of mamma microvessels, due
to newborn-pathological, type I, sub-
type (a) Oncological, EBDs (Stagnaro
and Stagnaro-Neri, 2004a; Stagnaro and
Caramel, 2010), conditio sine qua non of
breast cancer (Stagnaro, 2009).
In spite of genetic testing, bedside
ascertaining particularly breast cancer IRR
in well-defined breast quadrant(s) allows
physicians to perform an efficient malig-
nancy primary prevention in a few min-
utes. In addition, testing for mutations
breast cancer susceptibility genes or for
their diminished expression adds to the
ability to assess breast cancer IRR at an
individual level, because local biological
activity, examined with the aid of QBS,
results abnormal.
Really, bymeans of sophisticated semei-
otics images we cannot localize in mamma
quadrant(s) the possible IRR of breast
cancer, in BRCA 1, or BRCA1 mutation,
E1373X in exon 12 and BRCA 2 in exons
9, 10, 11, 17, 18, and 23 positive women
(and men) (Stagnaro-Neri and Stagnaro,
1995; Stagnaro, 2004, 2009; Stagnaro and
Stagnaro-Neri, 2004a,b; Stagnaro, 2008;
Stagnaro and Caramel, 2010; Caramel
and Stagnaro, 2011). In turn, by means
of QBS method, physicians can clin-
ically recognize firstly the Oncological
Terrain in a quantitative way (Stagnaro,
2011a), and then, but not in all cases,
the IRR of breast cancer: individuals with
Oncological Terrain do not show neces-
sarily also breast cancer IRR (Stagnaro,
2005a,b,c,d).
As a matter of fact, breast cancer,
bedside subdivided regarding ERs and
cytokine content, involves exclusively the
subject positive for Oncological Terrain
(Stagnaro, 2004; Stagnaro and Stagnaro-
Neri, 2004a,b; Stagnaro and Caramel,
2010; Caramel and Stagnaro, 2011).
We know that multiple cytokines, e.g.,
Interleukin 12 (IL-12), and Interleukin
23 (IL-23) were over-expressed in ER-
negative breast carcinoma and that the
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three major cytokines—MCP-1, MIP-
1beta and IL-8—were correlated to
inflammatory cell component, which
could account for the aggressiveness
of these tumors (Stagnaro-Neri and
Stagnaro, 1995; Stagnaro and Stagnaro-
Neri, 2004a; Stagnaro, 2005a,b,c,d, 2008;
Stagnaro and Caramel, 2010; Caramel and
Stagnaro, 2011). An early bedside diag-
nosis of breast cancer IRR allows both
a pre-primary and primary prevention
(Stagnaro and Caramel, 2013c) and detec-
tion, corroborated by several other QBS
signs such as the bedside evaluation of
glycocalyx (Stagnaro, 2011b).
Interestingly, from clinical and experi-
mental data there is an emerging evidence
that familial breast cancers, including
BRCA1 and its related forms, could
be estrogen-sensitive and interactions
between BRCA1 gene expression and
estrogens have been reported (Zheng et al.,
2001; Lindgren et al., 2002; Venkitaraman,
2002). Moreover, BRCA1 blocked the
expression of two endogenous estrogen-
regulated gene products in human breast
cancer cells (Ma et al., 2005). These knowl-
edge accounts for the reason QBS allows
differential diagnose between positive and
negative breast cancer at the bedside.
In addition, the presence of breast ER,
even localized in a mamma quadrant,
is bedside recognized rapidly and in a
reliable manner, by occurrence of type
I, associated, microcirculatory activation,
subsequent to oestrogene secretion pick
test, i.e., digital pressure upon Estrogen-
RH centers, lasting 15 s (Stagnaro and
Stagnaro-Neri, 2004a).
On the contrary, in absence of ERs
local microcirculatory blood-flow per-
sists unchanged, evaluated as the latency
time of mamma-gastric aspecific reflex
(Stagnaro and Stagnaro-Neri, 2004a;
Stagnaro, 2005a,b,c,d), As far as assess-
ing cytokine levels in the breast (or in all
other biological systems), it is sufficient
to know that, in health, intense breast
trigger-points stimulation by finger nail,
i.e., it brings about a gastric aspecific reflex
after 10 s latency time. On the contrary,
in presence of cytokines, latency time of
this reflex is lower and it results inversely
related to the underlying cytokine
level.
Mutations of BRAC1 and BRAC2
genes have been linked to hereditary
breast and ovarian cancer. Inheriting
these mutations, the risk of developing
breast/ovarian cancer generally increases,
but genetic tests cannot occur in every lab-
oratory. QBS allows physicians to bedside
recognize in quantitative way and precisely
localize from birth both breast cancer IRR
and the presence of BRCA-1 as well as
BRCA-2 mutations. In conclusion, with
the simple use of the stethoscope, QBS
diagnostic method is useful for a large
scale clinical diagnosis of Oncological
Terrain-Dependent and breast cancer
IRR, so allowing an effective primary and
pre-primary prevention.
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